US-EU Index Rebalances / Quantitative Researcher, ORTEX

Dimitris Ioannidis

US-EU Index Rebalances / Quantitative Researcher

Global Financial Data and Analytics Platform

ORTEX

ORTEX is a global financial data and analytics platform providing real-time securities lending and short interest data, index rebalance data, holdings and insider transactions, trading signals, corporate actions and news,  stock machine learning and factor scores and other analytics. The majority of the data are downloadable and accessible through APIs.

Index Rebalance

<ul>
<li>
<a href="https://www.smartkarma.com/entities/costar-group-inc" target="_blank" data-smartkarma-citation="entities:16907:1" rel="noopener">Costar Group (CSGP US)</a> will be deleted from Nasdaq100 on 15 May 2026 due to the fast-exit rule, which has been implemented for the last time with the old methodology.</li>
<li>
<a href="https://www.smartkarma.com/entities/lumentum-holdings-inc" target="_blank" data-smartkarma-citation="entities:12529:1" rel="noopener">Lumentum Holdings (LITE US)</a> will be added to the index replacing <a href="https://www.smartkarma.com/entities/costar-group-inc" target="_blank" data-smartkarma-citation="entities:16907:1" rel="noopener">Costar Group (CSGP US)</a>.</li>
<li>
<a href="https://www.smartkarma.com/entities/coreweave-inc" target="_blank" data-smartkarma-citation="entities:44471:1" rel="noopener">CoreWeave (CRWV US)</a>, <a href="https://www.smartkarma.com/entities/medline-inc" target="_blank" data-smartkarma-citation="entities:45954:1" rel="noopener">Medline (MDLN US)</a> and <a href="https://www.smartkarma.com/entities/teradyne-inc" target="_blank" data-smartkarma-citation="entities:13088:1" rel="noopener">Teradyne Inc (TER US)</a> are now the top addition candidates to replace the upcoming deletions in June 2026 with the new methodology.</li>
</ul>



Costar Group (CSGP US) will be deleted from Nasdaq100 on 15 May 2026 due to the fast-exit rule, which has been implemented for the last time with the old methodology.

Lumentum Holdings (LITE US) will be added to the index replacing Costar Group (CSGP US).

CoreWeave (CRWV US), Medline (MDLN US) and Teradyne Inc (TER US) are now the top addition candidates to replace the upcoming deletions in June 2026 with the new methodology.


Lumentum (LITE US): Nasdaq100 Inclusion Driven by Costar’s Fast‑Exit

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medline-inc" target="_blank" data-smartkarma-citation="entities:45954:1" rel="noopener">Medline (MDLN US)</a> goes public on 17 December on Nasdaq with an estimated market cap of $40bn, 27% lower than the consensus of $55bn.</li>
<li>Inclusion in US indices is expected in March 2026, as the security meets US eligibility criteria before the lock-up expiry.</li>
<li>Inclusion in Global indices is expected in May and June 2026 with a potential delay to August due to low float cap.</li>
</ul>



Medline (MDLN US) goes public on 17 December on Nasdaq with an estimated market cap of $40bn, 27% lower than the consensus of $55bn.
Inclusion in US indices is expected in March 2026, as the security meets US eligibility criteria before the lock-up expiry.
Inclusion in Global indices is expected in May and June 2026 with a potential delay to August due to low float cap.


Medline (MDLN US): Global & US Index Inclusion; Overestimated Valuation?

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Medline Industries has quickly become one of the most closely watched healthcare IPOs in recent months.</li><li>After going public in late 2025 in what was the year’s largest listing, the medical supply giant saw its stock surge roughly 58% from its debut price.</li><li>Now, only months later, several of its largest shareholders—including major private equity sponsors—are moving to sell a large portion of their holdings in a transaction worth about $3.4 billion.</li></ul>

Medline Industries has quickly become one of the most closely watched healthcare IPOs in recent months.After going public in late 2025 in what was the year’s largest listing, the medical supply giant saw its stock surge roughly 58% from its debut price.Now, only months later, several of its largest shareholders—including major private equity sponsors—are moving to sell a large portion of their holdings in a transaction worth about $3.4 billion.

Medline’s Stock Jumped 58% — So Why Are Its Largest Investors Selling Now?

<ul>
<li>
<a href="https://www.smartkarma.com/entities/walmart-inc" target="_blank" data-smartkarma-citation="entities:11134:1" rel="noopener">Walmart (WMT US)</a> is now eligible for Nasdaq100 following its listing change from NYSE to Nasdaq on 9 December 2025, marking the largest exchange transfer in history.</li>
<li>The listing transfer was completed after the December 2025 annual review cut-off, so Nasdaq100 inclusion is anticipated by December 2026.</li>
<li>Forecasted passive fund demand upon inclusion is ~600m shares, $70bn and 25 ADV.</li>
</ul>



Walmart (WMT US) is now eligible for Nasdaq100 following its listing change from NYSE to Nasdaq on 9 December 2025, marking the largest exchange transfer in history.
The listing transfer was completed after the December 2025 annual review cut-off, so Nasdaq100 inclusion is anticipated by December 2026.
Forecasted passive fund demand upon inclusion is ~600m shares, $70bn and 25 ADV.


Walmart (WMT US): Unwrapping Nasdaq100 Inclusion Following Listing Transfer

<ul>
<li>All eligible US IPOs that went public from 1 November 2025 to 31 January 2026 will be added to a major US index in March 2026.</li>
<li>
<a href="https://www.smartkarma.com/entities/medline-inc" target="_blank" data-smartkarma-citation="entities:45954:1" rel="noopener">Medline (MDLN US)</a> is expected to be the largest IPO addition in terms of market cap at a valuation of $60bn following its listing on 17 December 2025.</li>
<li>
<a href="https://www.smartkarma.com/entities/beta-technologies-inc" target="_blank" data-smartkarma-citation="entities:45894:1" rel="noopener">BETA Technologies (BETA US)</a> is projected to be included in the lower size segment following a 50% price tumble since its IPO on 4 November.</li>
</ul>


All eligible US IPOs that went public from 1 November 2025 to 31 January 2026 will be added to a major US index in March 2026.

Medline (MDLN US) is expected to be the largest IPO addition in terms of market cap at a valuation of $60bn following its listing on 17 December 2025.

BETA Technologies (BETA US) is projected to be included in the lower size segment following a 50% price tumble since its IPO on 4 November.


US Index IPO Forecast - Mar26: 8 Additions Including Medline & BETA Technologies

United States

Medline Industries is a medical supply company, manufacturer and distributor.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Medline (MDLN US)

Lumentum (LITE US): Nasdaq100 Inclusion Driven by Costar’s Fast‑Exit

Costar will be removed from Nasdaq100 via fast‑exit on 15 May with Lumentum replacing it, while Medline, CoreWeave and Teradyne are the top...

Dimitris Ioannidis

Medline (MDLN US): Global & US Index Inclusion; Overestimated Valuation?

MDLN went public on 17 Dec 2025 and is projected to be added to Global Standard and Global All World at the May26 and Jun26 reviews, respectively,...

Dimitris Ioannidis

Medline’s Stock Jumped 58% — So Why Are Its Largest Investors Selling Now?

Medline Industries has quickly become one of the most closely watched healthcare IPOs in recent months. After going public in late 2025 in what...

Baptista Research

Walmart (WMT US): Unwrapping Nasdaq100 Inclusion Following Listing Transfer

AstraZeneca (AZN) will delist its ADRs from Nasdaq and transition to a direct listing of its ordinary shares on the NYSE on 2 February. As a...

Dimitris Ioannidis

US Index IPO Forecast - Mar26: 8 Additions Including Medline & BETA Technologies

MDLN is set to be the largest US IPO index addition in March with a $60bn market cap, while BETA and YSS are poised for significant September...

Dimitris Ioannidis

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)